BMY Aug 2024 46.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.4400

+0.0700

(+18.92%)

At close: 03:32PM EDT

Loading interactive chart...

Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J., June 20, 2024--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024